MORE THAN 35 YEARS OF EXPERIENCE

Neuraxpharm,
your CNS Specialist

Finding solutions for disorders related to the central nervous system.
Scroll to explore

Driving change

Neuraxpharm
Commitment

1 in 4 people in the world will be affected by mental or neurological disorders at some point in their lives. Roughly every family will have at least one afflicted person in the home.

The wellbeing of those suffering from these disorders is at the heart of all we do. They are the center around whom we investigate and create our solutions.

Our drive and commitment have led us into a leadership position in Europe, specializing in high-quality yet affordable pharmaceuticals for the treatment of central nervous system disorders.

We think of the doctors, the pharmacists, the caretakers and the families. We are your expert CNS specialist.

Health and wellness

Visit our section on Health and wellness and start taking care of yourself

Neuraxpharm
News

As experts in CNS disorders, we bring you the latest news, product launches and innovative initiatives we constantly undertake to always stay ahead of developments in the CNS area.

Neuraxpharm Blog

Understand more about psychiatric and neurological disorders. Our team of health care professionals and expert journalists across Europe works to consistently bring you scientifically solid, trustable information to answer your concerns.

Multiple sclerosis

Cognitive impairment in Multiple Sclerosis: a reality to treat as early as possible

Cognitive impairment has been reported at all phases and all subtypes of multiple sclerosis (MS). The severity and type of cognitive impairment varies among individuals and can be observed both in early and in later stages. We should promote primary prevention of cognitive decline, in part through interventions and healthy lifestyles that promote brain maintenance.

Multiple sclerosis

MRI is a test that provides images of the body (brain and spinal cord in MS) using strong magnetic field and radio waves, but not radiation. It allows earlier diagnosis and treatment, as well as monitorization of the progression of MS by keeping track of any new lesions that may have occurred since initial diagnosis.

Multiple sclerosis

Approximately 85% of people diagnosed with multiple sclerosis present a relapsing-remitting disease course. This means that symptoms of a clinical relapse typically arise over days, worsen over several weeks and then gradually subside over several weeks or months.

Epilepsy

Juvenile Myoclonic Epilepsy (JME) is classified among Idiopathic Generalized Epilepsies, that is, among epilepsies caused exclusively by genetic predisposition. It can affect normal adolescents and young adults, with an age of onset ranging from 10 to 25 years. All patients present myoclonic jerks, which give the name to the syndrome, that is, rapid flexion jerks of the upper limbs.